Zimbabwe has turned down a substantial American health deal valued at $367m (272 million pounds) over five years over Washington's insistence on confidential information.
The decision became public after a official document dated December was leaked, which showed Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
An official representative has since clarified that the United States was seeking biological samples for research and profit while was unwilling to guarantee the resulting advantages from any future treatments.
"We will now turn to the difficult and regrettable process of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had furnished more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged continued dialogue to find a deal agreeable to both sides so the country's vital HIV treatment initiative can be sustained.
Broader Context
This rejection follows a comparable situation in Kenya, where a court halted a similar deal with the US after concerns were raised about the safety of Kenyans' medical information.
Since returning to office last year, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump claimed its expenditure was "wasteful" and his administration was pursuing government-to-government deals to boost transparency and accountability.
Based on statements, 16 nations in Africa have so far signed these new agreements, representing more than $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation would have delivered immense advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently on HIV treatment through American-funded initiatives," Tremont commented.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"Our nation was requested to provide its genetic material and health information indefinitely, with no equivalent assurance of access to any scientific breakthroughs – like new medicines or tests – that might result from that provided information," Mangwana explained.
"Effectively, our country would provide the basic resources for medical research with no assurance that the end products would be accessible to our people if a future pandemic emerge."
National Interest and International Frameworks
Mangwana further noted that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending systems already set up via the international organization.
The spokesperson cited its Pandemic Benefit-Sharing scheme designed to deal with future global health emergencies.
"This mechanism is designed to ensure that when a nation provides its information, the benefits – including medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to develop them."
These objections over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We welcome further dialogue with our US partners on how future co-operation could be arranged in a way that honours the independence and interests of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but recommended that negotiations need to persist considering much of the nation's HIV programmes relied on international support.
"If specific concerns arise, including those relating to information security or implementation frameworks, these can frequently be addressed via technical clarification and negotiated safeguards," it added.
The situation highlights the continuing debate between receiving much-needed international aid and protecting a country's data in an ever more data-driven world.